Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18739493 | METHODS OF PREPARING CANNABINOIDS OR DERIVATIVES THEREOF | June 2024 | December 2024 | Allow | 6 | 1 | 0 | No | No |
| 18667992 | TREATMENT OF PAIN AND NEUROLOGICAL CONDITIONS | May 2024 | February 2025 | Abandon | 9 | 1 | 0 | Yes | No |
| 18436995 | KRAS G12D Proteolysis Targeting Chimeras | February 2024 | August 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18435413 | METHODS FOR TREATING CANCER | February 2024 | March 2025 | Allow | 14 | 2 | 1 | No | No |
| 18422517 | Methyl (R)-2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1H-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl (R)-2- (Fluoromethyl)-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Pyridine-3-Carboxylate As Cav1.2 Activators | January 2024 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18416065 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | January 2024 | June 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18409773 | SELECTIVE HYDROGENATION CATALYST OF a,B-UNSATURATED KETONE USING ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOARYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(2-MERCAPTOQUINOLATO)(PiPr3)2 MOIETIES | January 2024 | March 2024 | Allow | 2 | 0 | 0 | No | No |
| 18577854 | A PROCESS AND PLANT FOR THE SYNTHESIS OF UREA AND MELAMINE | January 2024 | April 2025 | Allow | 15 | 2 | 1 | No | No |
| 18405177 | SELECTIVE REDUCTION CATALYST OF a,B-UNSATURATED KETONE USING ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOARYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(8-MERCAPTOQUINOLATO(PiPr3)2 MOIETIES | January 2024 | March 2024 | Allow | 3 | 0 | 0 | No | No |
| 18403509 | METHODS OF PREPARING CANNABINOIDS OR DERIVATIVES THEREOF | January 2024 | March 2024 | Allow | 2 | 2 | 0 | No | No |
| 18545312 | NRF2 ACTIVATOR | December 2023 | May 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18535036 | TREATMENT FOR CELLULITIS AND PRE-OPERATIVE TREATMENT | December 2023 | April 2025 | Allow | 16 | 1 | 0 | No | No |
| 18532000 | 6-(3-HYDROXYPHENYL)-2-METHOXY-4-(3-METHYLPHENYL)NICOTINONITRILE AS AN ANTIMICROBIAL COMPOUND | December 2023 | February 2024 | Allow | 2 | 0 | 0 | No | No |
| 18532962 | ORAL BENDAMUSTINE FORMULATIONS | December 2023 | June 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18524489 | METHODS OF TREATING CANCER | November 2023 | June 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18518738 | 2-(2-ETHOXYETHOXY)-6-PHENYL-4,4'-BIPYRIDINE-3-CARBONITRILE AS AN ANTIMICROBIAL COMPOUND | November 2023 | January 2024 | Allow | 2 | 0 | 0 | No | No |
| 18512910 | SUBSTITUTED N-PROPYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES | November 2023 | May 2025 | Allow | 18 | 3 | 1 | Yes | No |
| 18506737 | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4- YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID AND ITS CRYSTALLINE FORMS FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | November 2023 | August 2024 | Allow | 10 | 3 | 0 | No | No |
| 18381554 | P2X7 MODULATORS | October 2023 | October 2024 | Allow | 12 | 1 | 0 | No | No |
| 18482278 | Crystalline Forms 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1- YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2- Enenitrile | October 2023 | February 2025 | Allow | 16 | 2 | 0 | No | No |
| 18377561 | INHALABLE IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF | October 2023 | February 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18479690 | TLR 9 INHIBITORS | October 2023 | February 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18373376 | LARGE-SCALE METHODS OF UNIFORMLY COATING PACKAGING SURFACES WITH A VOLATILE ANTIMICROBIAL TO PRESERVE FOOD FRESHNESS | September 2023 | February 2025 | Allow | 17 | 1 | 1 | No | No |
| 18474840 | PROCESS FOR MAKING PALBOCICLIB | September 2023 | October 2024 | Allow | 13 | 1 | 0 | No | No |
| 18367909 | 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-(4-((2-THIOXOBENZO[d]OXAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTIMICROBIAL AND ANTICANCER COMPOUND | September 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18464731 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | September 2023 | March 2025 | Abandon | 18 | 2 | 1 | No | No |
| 18464156 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | September 2023 | December 2024 | Allow | 16 | 1 | 0 | No | No |
| 18239337 | METHODS OF SYNTHESIZING 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL] PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE | August 2023 | May 2024 | Allow | 9 | 0 | 0 | No | No |
| 18239087 | COMPOSITIONS AND METHODS FOR STORAGE STABLE OPHTHALMIC DRUGS | August 2023 | September 2024 | Allow | 12 | 2 | 0 | Yes | No |
| 18235486 | PHARMACEUTICAL COMPOSITIONS COMPRISING SEPIAPTERIN AND USES THEREOF | August 2023 | September 2024 | Allow | 13 | 1 | 0 | No | No |
| 18366998 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | August 2023 | January 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18230142 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND THEIR USE | August 2023 | February 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18364690 | ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS | August 2023 | January 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18347674 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | July 2023 | September 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18345772 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | June 2023 | August 2023 | Allow | 2 | 0 | 0 | No | No |
| 18339956 | ORGANIC COMPOUNDS | June 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18202751 | INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | May 2023 | March 2025 | Abandon | 21 | 2 | 0 | No | No |
| 18196863 | DIELS-ALDER CONJUGATION METHODS | May 2023 | April 2025 | Allow | 23 | 3 | 1 | No | No |
| 18144695 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | May 2023 | June 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18314060 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | May 2023 | August 2024 | Allow | 15 | 1 | 0 | No | No |
| 18311171 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | May 2023 | January 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18140333 | METHOD FOR PRODUCING AROMATIC NITRILE COMPOUND AND METHOD FOR PRODUCING CARBONATE ESTER | April 2023 | November 2024 | Allow | 19 | 2 | 0 | No | No |
| 18030775 | TOCOTRIENOLS DERIVATES, METHODS AND USES THEREOF | April 2023 | January 2024 | Allow | 9 | 2 | 0 | No | No |
| 18124906 | COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERY | March 2023 | March 2024 | Allow | 12 | 0 | 0 | No | No |
| 18117579 | NOVEL WATER REACTIVITY WITH NATURAL PRODUCTS | March 2023 | June 2023 | Allow | 3 | 0 | 0 | No | No |
| 18115436 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | February 2023 | October 2024 | Allow | 20 | 2 | 0 | No | No |
| 18110588 | Compositions and Methods for Treating Atopic Dermatitis | February 2023 | July 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18110577 | Compositions and Methods for Treating Atopic Dermatitis | February 2023 | July 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18107703 | CONTRACEPTIVE METHODS WITH IMPROVED PEARL INDEX | February 2023 | October 2024 | Allow | 20 | 4 | 0 | Yes | No |
| 18104610 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | February 2023 | October 2024 | Allow | 21 | 2 | 1 | No | No |
| 18161184 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | January 2023 | July 2024 | Allow | 18 | 1 | 1 | No | No |
| 18160323 | HIGHLY EFFICIENT PROCESS FOR THE PREPARATION OF 4-FLUORO-1H-PYRAZOLE OR SALTS THEREOF | January 2023 | April 2024 | Allow | 15 | 1 | 0 | No | No |
| 18147071 | ISOTOPOLOGUES SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF | December 2022 | October 2024 | Allow | 22 | 4 | 0 | Yes | No |
| 18084179 | PREPARATION METHOD OF TRILACICLIB AND PRECURSORS OF TRILACICLIB | December 2022 | January 2024 | Allow | 13 | 1 | 0 | No | No |
| 18065193 | Organic Electroluminescent Materials and Devices | December 2022 | July 2024 | Allow | 19 | 1 | 0 | No | No |
| 18064565 | IONIZABLE CATIONIC LIPIDS | December 2022 | March 2024 | Allow | 15 | 0 | 0 | No | No |
| 17986414 | TREATING PATIENTS HARBORING AN ISOCITRATE DEHYDROGENASE-1 (IDH-1) MUTATION | November 2022 | March 2025 | Abandon | 28 | 2 | 0 | No | No |
| 17982468 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | November 2022 | October 2024 | Abandon | 23 | 2 | 0 | No | No |
| 17977687 | Benzodioxane Modulators of Leukotriene A4 Hydrolase (LTA4H) for Prevention and Treatment of Aging-Associated Diseases | October 2022 | February 2024 | Allow | 16 | 3 | 1 | No | No |
| 17976168 | Targeting Mcl-1 to Enhance DNA Replication Stress Sensitivity for Cancer Therapy | October 2022 | October 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17975214 | COMPOUNDS FOR THE TREATMENT OF GLYCOGEN STORAGE DISORDERS | October 2022 | May 2024 | Allow | 18 | 1 | 0 | No | No |
| 18050396 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | October 2022 | May 2025 | Allow | 31 | 2 | 0 | No | No |
| 17971836 | METHODS OF TREATING PARKINSON'S DISEASE | October 2022 | August 2023 | Abandon | 10 | 1 | 0 | No | No |
| 17969519 | INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME | October 2022 | November 2024 | Allow | 25 | 2 | 0 | No | No |
| 17916065 | CHEMICAL COMPOUNDS, OPTOELECTRONIC ELEMENTS COMPRISING AT LEAST ONE NEW CHEMICAL COMPOUND, AND USE OF NEW CHEMICAL COMPOUNDS IN AN OPTOELECTRONIC ELEMENT | September 2022 | September 2024 | Allow | 23 | 1 | 1 | No | No |
| 17944228 | RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF TUBERCULOSIS | September 2022 | October 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17909834 | OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT | September 2022 | June 2025 | Allow | 33 | 0 | 0 | No | No |
| 17929957 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE ("NACK") AND METHODS FOR USE OF THE SAME | September 2022 | April 2024 | Allow | 19 | 1 | 0 | No | No |
| 17901504 | SYNTHESIS OF MDMA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDMA ISOMERS | September 2022 | January 2024 | Allow | 24 | 2 | 0 | No | No |
| 17899660 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | August 2022 | March 2025 | Allow | 31 | 3 | 0 | No | Yes |
| 17898776 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR MODULATING HEMATOPOIETIC STEM CELLS AND HEMATOPOIESIS | August 2022 | February 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17822484 | SYSTEM USING A METHOD FOR SEARCHING AND IDENTIFYING A GENETIC CONDITION PRODROMAL OF THE ONSET OF SOLID TUMORS | August 2022 | February 2025 | Abandon | 30 | 2 | 0 | No | No |
| 17895619 | PROCESS FOR SYNTHESIZING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)-PYRIDIN-3-YL)METHOXY)BENZALDEHYDE | August 2022 | August 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17801328 | IMMUNOMODULATING TRIFLUOROMETHYL-AMINAL AZALIDES | August 2022 | June 2025 | Allow | 34 | 1 | 0 | No | No |
| 17884493 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | August 2022 | January 2024 | Allow | 17 | 0 | 0 | No | No |
| 17818052 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | August 2022 | March 2025 | Allow | 31 | 0 | 0 | No | No |
| 17875508 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | July 2022 | June 2024 | Allow | 23 | 1 | 0 | No | No |
| 17874399 | NEW CRYSTALLINE POLYMORPHS OF RIVOCERANIB AND RIVOCERANIB MESYLATE | July 2022 | March 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17814599 | INTERMITTENT DOSING OF MDM2 INHIBITOR | July 2022 | May 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17867431 | COMPOUNDS AND FORMS OF TREATMENT FOR FEMALE SEXUAL DISORDERS | July 2022 | November 2023 | Allow | 16 | 0 | 0 | No | No |
| 17865236 | DIHYDROOXADIAZINONES | July 2022 | March 2023 | Allow | 8 | 2 | 0 | Yes | No |
| 17862255 | DIHYDROOXADIAZINONES | July 2022 | November 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17859505 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | July 2022 | October 2023 | Allow | 16 | 0 | 0 | No | No |
| 17848976 | METHODS OF TREATING NON-HODGKIN LYMPHOMA USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | June 2022 | April 2024 | Allow | 22 | 1 | 0 | No | No |
| 17849243 | MACROMOLECULE COMPOUNDS | June 2022 | January 2024 | Abandon | 19 | 2 | 1 | No | No |
| 17808368 | PREPARATION OF HALOGEN ANALOGS OF PICLORAM | June 2022 | February 2024 | Allow | 20 | 1 | 0 | No | No |
| 17848150 | SOLID FORMS OF 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | June 2022 | May 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17808388 | PROTEIN KINASE C INHIBITORS FOR TREATMENT OF UVEAL MELANOMA | June 2022 | September 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17844901 | SALTS OF A COMPOUND AND THE CRYSTALLINE FORMS THEREOF | June 2022 | May 2024 | Allow | 23 | 2 | 0 | No | No |
| 17841166 | PYRAZOLOPYRIDINES AND TRIAZOLOPYRIDINES AS A2A / A2B INHIBITORS | June 2022 | September 2023 | Allow | 15 | 0 | 0 | No | No |
| 17807061 | METHODS AND PROCESSES FOR THE PREPARATION OF KDM1A INHIBITORS | June 2022 | August 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17839246 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | June 2022 | April 2025 | Allow | 34 | 0 | 0 | No | No |
| 17836596 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | June 2022 | August 2024 | Allow | 26 | 3 | 0 | No | No |
| 17749452 | NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN AND CRYSTALLINE PHASES OF SYNTHETIC INTERMEDIATES | May 2022 | August 2023 | Allow | 14 | 0 | 0 | No | No |
| 17739358 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | May 2022 | January 2024 | Allow | 21 | 1 | 0 | No | No |
| 17733404 | PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF | April 2022 | April 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17728325 | COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS | April 2022 | November 2024 | Allow | 30 | 2 | 1 | No | No |
| 17728876 | Compositions and Methods for Treating Atopic Dermatitis | April 2022 | April 2024 | Allow | 24 | 2 | 0 | No | No |
| 17727788 | THERMAL CONVERSION OF CBDA AND OTHER CARBOXYLIC CANNABINOIDS | April 2022 | April 2024 | Allow | 24 | 1 | 0 | No | No |
| 17724199 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | April 2022 | October 2024 | Abandon | 29 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SOLOLA, TAOFIQ A.
With a 64.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 30.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SOLOLA, TAOFIQ A works in Art Unit 1625 and has examined 1,381 patent applications in our dataset. With an allowance rate of 77.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 20 months.
Examiner SOLOLA, TAOFIQ A's allowance rate of 77.2% places them in the 36% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by SOLOLA, TAOFIQ A receive 1.38 office actions before reaching final disposition. This places the examiner in the 29% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SOLOLA, TAOFIQ A is 20 months. This places the examiner in the 87% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +12.0% benefit to allowance rate for applications examined by SOLOLA, TAOFIQ A. This interview benefit is in the 51% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 30.5% of applications are subsequently allowed. This success rate is in the 52% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 60.6% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 115.8% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 80% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 77.3% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 63.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 55.6% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 7.4% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.1% of allowed cases (in the 58% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.